OBJECTIVE: The inhibitory proteins, IkappaBs, regulate the activity of nuclear factor kappa-beta (NF-kappaB), which is implicated in tumorigenesis by regulating expression of a variety of genes involved in cellular transformation, proliferation, invasion, angiogenesis and metastasis. Variants in the genes encoding IkappaBs may be involved in cancer development through the activation of NF-kappaB. The objective of this study was to investigate the susceptibility of an A to G variation (rs696) in the 3' UTR of NFKBIA (encoding IkappaBalpha) to colorectal cancer (CRC) and the association of this polymorphism with clinicopathologic variables in CRC patients. MATERIAL AND METHODS: A case-control study was carried out on a Swedish (155 CRCs, 438 controls) and a Chinese population (199 CRCs, 577 controls). The genotype of NFKBIA was determined by PCR-restriction fragment length polymorphism. RESULTS: The frequency of the AG genotype was increased in the Chinese patients >or=50 years of age compared with the Chinese controls (odds ratio (OR)=3.06, 95% confidence interval (CI)=1.55-6.02, p=0.001), even when adjusted for age (OR=3.20, 95% CI=1.61-6.38, p=0.001). The GG genotype of NFKBIA was related to a poorer survival rate in the Swedish patients, independent of gender, age, tumour location, Dukes' stage and differentiation (hazard ratio = 3.10, 95% Cl=1.28-7.60, p=0.01). CONCLUSIONS: Chinese individuals >or=50 years of age carrying the AG genotype of NFKBIA may be at an increased risk of developing CRC, and the GG genotype of NFKBIA may be considered as a prognostic factor for Swedish CRC patients.
OBJECTIVE: The inhibitory proteins, IkappaBs, regulate the activity of nuclear factor kappa-beta (NF-kappaB), which is implicated in tumorigenesis by regulating expression of a variety of genes involved in cellular transformation, proliferation, invasion, angiogenesis and metastasis. Variants in the genes encoding IkappaBs may be involved in cancer development through the activation of NF-kappaB. The objective of this study was to investigate the susceptibility of an A to G variation (rs696) in the 3' UTR of NFKBIA (encoding IkappaBalpha) to colorectal cancer (CRC) and the association of this polymorphism with clinicopathologic variables in CRCpatients. MATERIAL AND METHODS: A case-control study was carried out on a Swedish (155 CRCs, 438 controls) and a Chinese population (199 CRCs, 577 controls). The genotype of NFKBIA was determined by PCR-restriction fragment length polymorphism. RESULTS: The frequency of the AG genotype was increased in the Chinese patients >or=50 years of age compared with the Chinese controls (odds ratio (OR)=3.06, 95% confidence interval (CI)=1.55-6.02, p=0.001), even when adjusted for age (OR=3.20, 95% CI=1.61-6.38, p=0.001). The GG genotype of NFKBIA was related to a poorer survival rate in the Swedish patients, independent of gender, age, tumour location, Dukes' stage and differentiation (hazard ratio = 3.10, 95% Cl=1.28-7.60, p=0.01). CONCLUSIONS: Chinese individuals >or=50 years of age carrying the AG genotype of NFKBIA may be at an increased risk of developing CRC, and the GG genotype of NFKBIA may be considered as a prognostic factor for Swedish CRCpatients.
Authors: Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh Journal: N Engl J Med Date: 2010-12-22 Impact factor: 91.245
Authors: Abdullateef A Alzolibani; Ahmed Settin; Ahmed Ali Ahmed; Hisham Ismail; Noor Elhefni; Ahmad A Al Robaee Journal: Int J Health Sci (Qassim) Date: 2015-01
Authors: Liang Qiao; Yan Wang; Roberta Pang; Jide Wang; Yun Dai; Juan Ma; Qing Gu; Zesong Li; Yusheng Zhang; Bing Zou; H Y Lan; Benjamin C Y Wong Journal: Pathol Oncol Res Date: 2008-08-28 Impact factor: 3.201
Authors: Kristin L White; Robert A Vierkant; Catherine M Phelan; Brooke L Fridley; Stephanie Anderson; Keith L Knutson; Joellen M Schildkraut; Julie M Cunningham; Linda E Kelemen; V Shane Pankratz; David N Rider; Mark Liebow; Lynn C Hartmann; Thomas A Sellers; Ellen L Goode Journal: BMC Cancer Date: 2009-06-06 Impact factor: 4.430